论文部分内容阅读
Endoglin(CD105)是最可靠的内皮细胞增殖标志物,在肿瘤新生血管中过表达。基于Endoglin的靶向显像可以了解恶性肿瘤的血管生成情况,并为新生血管靶向治疗提供依据。在生物治疗方面,单克隆抗体在恶性肿瘤治疗中的地位越来越重要,因而基于抗Endoglin抗体的肿瘤靶向治疗在近年来受到广泛关注。本文将对基于Endoglin的靶向诊断及治疗作一简要综述。
Endoglin (CD105) is the most reliable marker of endothelial proliferation and is overexpressed in tumor neovascularization. Endoglin-based targeted imaging can understand the angiogenesis of malignant tumors and provide a basis for neovascular targeted therapy. In the field of biotherapy, the role of monoclonal antibodies in the treatment of malignant tumors is becoming more and more important. Therefore, tumor-targeted therapy based on anti-Endoglin antibodies has drawn extensive attention in recent years. This article will be based on Endoglin targeted diagnosis and treatment for a brief review.